{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.1","upperLimit":"91.6","value":"82.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission \\[CR\\] + complete remission with incomplete marrow recovery \\[CRi\\] + nodular partial remission \\[nPR\\] + partial remission \\[PR\\]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG000","title":"Safety Expansion Cohort"}],"paramType":"NUMBER","populationDescription":"All treated participants in the Safety Expansion Cohort","reportingStatus":"POSTED","timeFrame":"Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up","title":"Overall Response Rate (ORR) (Safety Expansion Cohort)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}